



Newsletter 1

Welcome to the first edition of the ATMP XB newsletter.

ATMP XB brings together partners from Flanders and the Netherlands to strengthen the future of advanced cell and gene therapies.

In this newsletter, we are excited to share the vision, objectives and collaborations that are shaping this ambitious project and helping position our region as a leading European hub for advanced therapies.

Want to stay updated? Visit our [website](#) and follow us on [LinkedIn](#).

Want to receive future editions of this newsletter in your mailbox? Subscribe [here](#).



About us

ATMP XB is a Flemish-Dutch cross-border initiative focused on strengthening the ecosystem for advanced therapies. The project is supported through the Interreg Vlaanderen-Nederland programme (European Union) and co-financed through VLAIO and the Province of Antwerp.

With a total investment of €3.5 million, the consortium aims to build one of Europe's strongest ATMP clusters by improving: quality assurance and control, safe production, innovation capacity and collaboration between academia, healthcare and industry.

Project objectives

Strengthening quality infrastructure

ATMP XB establishes and reinforces critical infrastructure for the production and testing of ATMPs and biomaterials. A key component is the creation of a joint Flemish-Dutch QA/QC Competence Centre offering advanced quality testing services.



Accelerating innovation

The project stimulates innovation by developing technologies that make ATMP production faster, safer and more efficient. Through a dedicated voucher programme, SMEs receive support in solving current QA/QC challenges such as sterility and efficacy testing.

Combination product development

ATMP XB also focuses on combining advanced therapies with medical devices. This includes developing plug-and-play delivery systems that allow safe and efficient administration of cell therapies.



Education & talent development

The project creates a learning network and training centre where companies, researchers and students build expertise in ATMP development and analytical techniques. Activities include:





- specialized courses,
- upskilling programmes,
- expert round tables,
- and coaching for innovators.

Project partners



Biovia is the health innovation cluster for Flanders, Belgium, uniting human and planetary health into one vibrant ecosystem.



POM Antwerp strengthens regional innovation through specialized infrastructure, research-industry collaboration and targeted ecosystem support.



at.las ATMP connects Antwerp's cell, gene and tissue therapy expertise to accelerate innovation, collaboration and translational advanced therapy development.



RegMed XB unites academia, industry and patient organizations to accelerate regenerative medicine breakthroughs through translational research collaborations.




Sure Laboratories accelerates life science R&D and quality control through GMP- and ISO 13485-compliant microbiological testing services.



KdG University of Applied Sciences and Arts delivers practice-based education and innovation-driven research aligned with industry and societal needs.



QbD Group supports pharma and MedTech companies worldwide with regulatory, clinical, quality, validation and ATMP expertise across product lifecycles.



Anabiotec delivers end-to-end analytical, CMC, and multi-omics solutions for biopharmaceutical, biologics, and cell and gene therapy development.



Smart Biomaterials Center accelerates smart biomaterial and regenerative medicine commercialization through translational platforms, industrialization facilities and innovation.



Idevax is ISO13485 certified for developing precision intradermal injection devices for preventive and therapeutic vaccines emphasizing innovation, usability and quality.



UZ Gent advances innovative patient care, translational research and ATMP development through excellence, empathy, efficiency and pioneering healthcare innovation.



anicells supports clinical cell therapy development through GMP-compliant manufacturing infrastructure and translational services accelerating patient access to advanced therapies.



News



OHMX.bio highlights Next-Generation Biopharma QC innovations at London Calling

Anabiotec (Business Unit OHMX bio as part of Anacura), partner within the ATMP XB project, showcased its cutting-edge nanopore sequencing expertise for biopharma quality control at the London Calling conference. Steven Verbruggen, Head of Bio-IT at OHMX bio, presented innovative long-read sequencing workflows and bioinformatics pipelines that improve QC testing for mRNA therapeutics, recombinant cell lines and future AAV products. The technology supports faster, more robust and GMP-ready quality control for next-generation biologics and advanced therapies.

Upcoming events



3-4/6/2026

Knowledge for Growth

No borders, just breakthroughs

Knowledge for Growth is where Europe's health innovation leaders stop talking in silos. Medical biotech, medtech, digital health, agtech and industrial biotech come together

[Join Now](#)



10-11/6/2026

RegMed XB Annual Conference

Collaborate to regenerate

Where leaders, innovators and professionals from across the field come together to exchange ideas, explore trends and drive progress in regenerative medicine.

[Join Now](#)



10/11/2026

Science for Health

Immunology reengineered: A new platform for precision medicine

Science for Health 2026 will explore how breakthroughs in immune-based technologies can be translated into precision treatments for rare and complex diseases.

[Join Now](#)



ATMP XB is co-funded by the European Union through Interreg and co-financed by VLAIO and the Province of Antwerp.



[Doorsturen](#)

[Voorkeuren aanpassen](#) | [Uitschrijven](#)